Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 36

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 Remaining Contractual Term (in years)  
    Weighted- Average Exercisable Price 
     
    Aggregate

Intrinsic

Value (1)

    Outstanding, March 31, 2025 
     14,632,859  
     2.40  
     2.1  
     2.40 

           -

    Granted and issued 
     470,000  
     0.83  
     2.83  
     0.83 

    Exercised 
     (70,000) 
     2.00  
     -  
     2.00 

    Expired 
     (58,778) 
     -  
     -  
     - 

    Outstanding, September 30, 2025 
     14,974,081  
    $2.33  
     1.58  
    $2.33 

    -

    (1)
    The
    aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing price
    of the Company’s common stock, which was $1.10 per share on September 30, 2025 and $.60 per share on March 31, 2025.

Stock-based compensation expense related to warrants was $92,728 and $109,378 for the three months ended September
30, 2025 and 2024, respectively, and $166,752 and $151,773 for the six months ended September 30, 2025 and 2024, respectively. As of September
30, 2025, unrecognized warrant expense totaled $815,049, which is expected to be recognized on a quarterly basis over the remaining 26-month
vesting period.

NOTE
14 – SEGMENT REPORTING

The
Company manages the business activities on a consolidated basis and operates in one reportable segment. The Company’s reportable
segment is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical
devices and therapeutics for animals. The segment is animal health products. As the Company has one reportable segment, sales and marketing,
research and development, including clinical trial expenses and general and administrative expenses are equal to consolidated results.
Financial results for the Company’s reportable segment have been prepared using a management approach, which is consistent with
the basis and manner